Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2 CAR VLP
- Development stage
- Preclinical
- Lead developer
- Ensoma
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
HER2 CAR VLP is an in vivo engineered, lineage-restricted multicellular immunotherapy developed by Ensoma. Utilizing Ensoma's Engenious platform, the therapy consists of a helper-dependent adenoviral virus-like particle (VLP) that targets CD46-positive cells, including long-term hematopoietic stem cells (LT-HSCs) and mature immune cells. The VLP delivers a large genetic payload (up to 35 kb) encoding lineage-restricted anti-HER2 chimeric antigen receptors (CARs) driven by T/NK-cell-specific and myeloid-specific promoters, alongside a hyperactive Sleeping Beauty transposase (SB100X) for stable genomic integration and an MGMTP140K cassette for chemotherapy-based enrichment. Upon in vivo administration, the platform generates a self-renewing reservoir of HER2-targeting CAR-T, CAR-NK, and CAR-macrophage (CAR-M) cells that cooperatively infiltrate, remodel, and control HER2-positive solid tumors.
- Other names
- Ensoma HER2 CAR VLPin vivo HER2 CAR VLP
02
Targets
CD46 (CD46 Molecule)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2 CAR VLP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2 CAR VLP.